Payment overview · 2025
General Payments
$61.79
4 reported records · 3 companies
Healthcare provider profile · identity verified
Timothy Scott Webb, DO
Allopathic & Osteopathic Physicians|Family Medicine · HOISINGTON, KS · NPI 1912961715
Verified facts
What the public records show
CMS Open Payments records show Timothy Scott Webb, DO received $61.79 in general payments during 2025 across 4 reported records.
Amgen Inc. accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.64 | 51.2% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $15.28 | 24.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.87 | 24.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.79 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.64 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 635 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 630 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 624 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 114 |
| Gabapentin | Gabapentin | 498 | 89 |
| Furosemide | Furosemide | 462 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 430 | 76 |
| Losartan Potassium | Losartan Potassium | 415 | 86 |
| Lisinopril | Lisinopril | 362 | 75 |
| Potassium Chloride | Potassium Chloride | 357 | 72 |
| Omeprazole | Omeprazole | 292 | 55 |
| Eliquis | Apixaban | 286 | 43 |
| Sertraline Hcl | Sertraline Hcl | 272 | 40 |
| Montelukast Sodium | Montelukast Sodium | 267 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 49 |
| Tramadol Hcl | Tramadol Hcl | 237 | 49 |
| Simvastatin | Simvastatin | 234 | 45 |
| Metformin Hcl | Metformin Hcl | 202 | 43 |
| Famotidine | Famotidine | 198 | 34 |
| Memantine Hcl | Memantine Hcl | 183 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 33 |
| Donepezil Hcl | Donepezil Hcl | 178 | 32 |
| Carvedilol | Carvedilol | 167 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 41 |
| Warfarin Sodium | Warfarin Sodium | 156 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 55 |
| Ozempic | Semaglutide | 144 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 136 | 26 |
| Trazodone Hcl | Trazodone Hcl | 136 | 32 |
| Prednisone | Prednisone | 134 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 21 |
| Jardiance | Empagliflozin | 123 | 16 |
| Bumetanide | Bumetanide | 122 | 21 |
| Metformin Hcl Er | Metformin Hcl | 121 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 32 |
| Bupropion Xl | Bupropion Hcl | 106 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 20 |
| Allopurinol | Allopurinol | 104 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 14 |
| Xarelto | Rivaroxaban | 87 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 24 |
| Finasteride | Finasteride | 77 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 12 |
| Mirtazapine | Mirtazapine | 73 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 72 | 14 |
| Meloxicam | Meloxicam | 72 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | suppressed |
| Alprazolam | Alprazolam | 68 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 14 |
| Cephalexin | Cephalexin | 62 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | suppressed |
| Spironolactone | Spironolactone | 61 | 24 |
| Buspirone Hcl | Buspirone Hcl | 58 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | suppressed |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 14 |
| Pregabalin | Pregabalin | 54 | 11 |
| Nystatin | Nystatin | 53 | 21 |
| Primidone | Primidone | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 35 |
| Novolog Flexpen | Insulin Aspart | 45 | 12 |
| Baclofen | Baclofen | 44 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 14 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 12 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 12 |
| Klor-Con M20 | Potassium Chloride | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Movantik | Naloxegol Oxalate | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | 16 |
| Torsemide | Torsemide | 29 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 17 |
| Methocarbamol | Methocarbamol | 26 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 23 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Novolog | Insulin Aspart | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Xcopri | Cenobamate | 16 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.79 · 4 records | Amgen Inc. | BEXSERO, BRUKINSA, EVENITY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error